Quick verdict
Hims & Hers is the better pick for most patients on overall scoring. Same-day prescription, no lock-in, and brand-name confidence. The famous $199 compounded era ended in March 2026 after the Novo Nordisk settlement; new patients now route to branded products only.
That said, Embla wins on specific dimensions. Embla is the closest thing the US market has to a Noom-meets-Calibrate hybrid that actually leans into the medication. Heavy behavioral coaching, branded-first prescribing, structured 12-month curriculum. Best for buyers who want the program to do half the work.
Side-by-side
| Hims & Hers | Embla | |
|---|---|---|
| Starts from | $199/mo (incl. medication) | $249/mo (+ med separate) |
| Lock-in | Month-to-month | 12-month commitment |
| Time to prescription | 1 day | 7 days |
| Consultation type | Asynchronous | Synchronous |
| Affiliate network | Impact | Impact |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| Hims & Hers | Embla | |
|---|---|---|
| Pricing transparency | 7/10 | 6/10 |
| Cancellation terms | 9/10 | 7/10 |
| Onboarding experience | 9/10 | 6/10 |
| Medication options | 7/10 | 7/10 |
| Member outcomes | 5/10 | 8/10 |
When to choose Hims & Hers
Patients who want a fast, low-friction async path to a branded GLP-1 prescription with predictable all-in monthly pricing.
When to choose Embla
Patients who tried meds-only and bounced, and want a structured behavior program alongside GLP-1.
FAQ
Is Hims & Hers cheaper than Embla?
Can I switch from Hims & Hers to Embla mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →